Shaping Best Practices For Standardized Medical Imaging In Clinic...( The Drug Infor...),Health

The Drug Information Association (DIA), in collaboration with FDA, the Medical Imaging Contrast Agent Association (MICAA), the Council on Radionuclides and Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), will host Medical Imaging Continuum: Path Forward for Advancing the Uses of Medical Imaging in the Development of New Biopharmaceutical Products (October 2-3; Bethesda, MD)

Horsham, PA (Vocus) August 26, 2008-- http://www.diahome.org/ [The Drug Information Association (DIA)], in collaboration with FDA, the Medical Imaging Contrast Agent Association (MICAA), the Council on Radionuclides and Radiopharmaceuticals (CORAR), PhRMA, and the American Medical Informatics Association (AMIA), will host http://www.diahome.org/ [Medical Imaging Continuum: Path Forward for Advancing the Uses of Medical Imaging in the Development of New Biopharmaceutical Products] (October 2-3; Bethesda, MD)

This workshop will provide updates on the harmonization and standardization of the key elements required to meet the FDA review process and Proposed Draft Regulatory Guidance of 2011. This effort is currently in progress with PhRMA, the Extended PhRMA Imaging Group, CORAR, MICAA and many other stakeholders who are shaping best practices for standardizing medical imaging in clinical trials, including academia, professional imaging societies, non-profit consortia, governmental agencies, and regulatory authorities.

Attendees will discuss "Metrics for Quantifying the Quality of Imaging Enterprises in Clinical Trials" and "How to Standardize Image Acquisition, Transfer, and Analysis." Potential outcomes will include:

• Endor
  '/>"/>